Nathalie Wauthoz

List of Publications by Year
in descending order

40 papers	1,727 citations	304743 22 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	2727 citing authors

#	Article	IF	Citations
1	Lycorine, the Main Phenanthridine Amaryllidaceae Alkaloid, Exhibits Significant Antitumor Activity in Cancer Cells That Display Resistance to Proapoptotic Stimuli: An Investigation of Structureâ”Activity Relationship and Mechanistic Insight. Journal of Medicinal Chemistry, 2009, 52, 6244-6256.	6.4	214
2	Lactose characteristics and the generation of the aerosol. Advanced Drug Delivery Reviews, 2012, 64, 233-256.	13.7	168
3	Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. Cancers, 2013, 5, 1020-1048.	3.7	126
4	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. Journal of Controlled Release, 2016, 227, 71-81.	9.9	123
5	New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. Molecular Pharmaceutics, 2018, 15, 899-910.	4.6	112
6	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Scientific Reports, 2017, 7, 1217.	3.3	105
7	Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. International Journal of Pharmaceutics, 2012, 428, 103-113.	5.2	55
8	How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. International Journal of Pharmaceutics, 2019, 561, 47-65.	5.2	55
9	New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. International Journal of Nanomedicine, 2012, 7, 5475.	6.7	51
10	Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 257-266.	4.3	50
11	Development of controlled-release cisplatin dry powders for inhalation against lung cancers. International Journal of Pharmaceutics, 2016, 515, 209-220.	5.2	46
12	In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 627-634.	4.3	45
13	Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorganic and Medicinal Chemistry, 2010, 18, 3823-3833.	3.0	40
14	Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia. International Journal of Nanomedicine, 2017, Volume 12, 8531-8543.	6.7	40
15	Phospholipids in pulmonary drug delivery. European Journal of Lipid Science and Technology, 2014, 116, 1114-1128.	1.5	39
16	Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment. Pharmaceutical Research, 2011, 28, 762-775.	3.5	37
17	The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. Cancers, 2019, 11, 329.	3.7	37
18	Tumor Targeting by Peptide-Decorated Gold Nanoparticles. Molecular Pharmaceutics, 2019, 16, 2430-2444.	4.6	37

#	Article	IF	Citations
19	In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. European Journal of Pharmaceutical Sciences, 2010, 39, 402-411.	4.0	36
20	Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy. International Journal of Pharmaceutics, 2016, 501, 148-159.	5.2	34
21	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity. International Journal of Oncology, 2013, 43, 575-585.	3.3	33
22	Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 46-54.	4.3	23
23	New Respirable and Fast Dissolving Itraconazole Dry Powder Composition for the Treatment of Invasive Pulmonary Aspergillosis. Pharmaceutical Research, 2012, 29, 2845-2859.	3.5	22
24	Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1237-1245.	3.3	22
25	New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy. International Journal of Oncology, 2015, 47, 1131-1142.	3.3	20
26	Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties. International Journal of Pharmaceutics, 2017, 517, 359-372.	5.2	19
27	Cyclic versus Hemi-Bastadins. Pleiotropic Anti-Cancer Effects: from Apoptosis to Anti-Angiogenic and Anti-Migratory Effects. Molecules, 2013, 18, 3543-3561.	3.8	18
28	Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects. Expert Opinion on Drug Delivery, 2021, 18, 333-354.	5.0	17
29	Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca²⁺ release. Journal of Cellular and Molecular Medicine, 2012, 16, 1421-1434.	3.6	13
30	Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend. International Journal of Pharmaceutics, 2018, 553, 47-56.	5.2	12
31	Stealth nanocarriers based sterosomes using PEG post-insertion process. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 31-38.	4.3	11
32	Nanomedicine-Based Inhalation Treatments for Lung Cancer. , 2019, , 249-268.		9
33	Optimization and scaling-up of ITZ-based dry powders for inhalation. Journal of Drug Delivery Science and Technology, 2017, 37, 147-157.	3.0	7
34	The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 164, 93-104.	4.3	6
35	Synthesis and plasma pharmacokinetics in CD-1 mice of a 18Î²-glycyrrhetinic acid derivative displaying anti-cancer activity. Journal of Pharmacy and Pharmacology, 2013, 65, 402-410.	2.4	5
36	Recent Developments in Inhaled Triazoles Against Invasive Pulmonary Aspergillosis. Current Fungal Infection Reports, 2014, 8, 331-342.	2.6	5

#	Article	IF	Citations
37	Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation. International Journal of Pharmaceutics, 2017, 530, 415-429.	5.2	5
38	Development of Neutralizing Multimeric Nanobody Constructs Directed against IL-13: From Immunization to Lead Optimization. Journal of Immunology, 2021, 207, 2608-2620.	0.8	5
39	Quantitative assay of capreomycin oleate levels in a drug formulation for inhalation with a fully validated HPLC method. Journal of Pharmaceutical and Biomedical Analysis, 2016, 120, 413-418.	2.8	2
40	Rosuvastatin and vascular oxidative stress induced by diesel exhaust particles. Acta Cardiologica, 2016, 71, 565-572.	0.9	1